NCT05050305 2024-07-16
Marizomib Central Nervous System (CNS)
Dana-Farber Cancer Institute
Phase 2 Withdrawn
Clinical Trials
3 trialsNCT03727841 2022-07-27
Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00461045 2017-12-19
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Celgene
Phase 2 Completed